Drug intelligence / Profile preview

KN059

Development stage: Preclinical
Lead developer: Suzhou Alphamab Co., Ltd.
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

KN059 is a preclinical-stage multi-specific domain antibody (dAb) being developed by Suzhou Alphamab Co., Ltd. for the treatment of infectious diseases, specifically targeting an unspecified orphan indication. Utilizing Alphamab's proprietary domain antibody platform, KN059 is engineered to bind multiple targets or epitopes simultaneously, which may provide a therapeutic advantage in treating complex or resistant infections. The specific molecular targets and detailed mechanism of action have not been disclosed by the company, but the asset is part of their innovative pipeline focusing on multi-specific biologics.

Beyond the preview

Go deeper on KN059.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN059.

Explore the full profile